selenomethionine has been researched along with Cancer of Prostate in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.50) | 18.7374 |
| 1990's | 1 (2.50) | 18.2507 |
| 2000's | 26 (65.00) | 29.6817 |
| 2010's | 11 (27.50) | 24.3611 |
| 2020's | 1 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bosland, MC; Deng, Y; Lü, J; Schlicht, MJ | 1 |
| Brawley, OW; Ford, LG; Minasian, LM; Parnes, HL | 1 |
| Bearden, JD; Blanke, CD; Christen, WG; Crowley, JJ; Darke, AK; Gaziano, JM; Glynn, RJ; Goodman, GE; Goodman, PJ; Klein, EA; Lad, TE; Lippman, SM; Minasian, LM; Thompson, IM | 1 |
| Alberts, DS; Darke, AK; Fales, L; Goodman, PJ; Jacobs, ET; Lance, P; Minasian, L; Roe, DJ; San Jose, J; Thompson, IM; Thompson, PA; Wang, F; Yee, M | 1 |
| Cecchini, MG; Klima, I; Peternac, D; Schwaninger, R; Studer, UE; Thalmann, GN | 1 |
| Gao, AC; Nadiminty, N | 1 |
| Boysen, C; Gulati, S; Kennedy, AR; Kopelovich, L; Rosenfeld, S; Stewart, J; Ware, J; Zhou, Z | 1 |
| Albanes, D; Arnold, KB; Baker, LH; Bearden, JD; Claudio, J; Coltman, CA; Cook, ED; Crawford, ED; Crowley, JJ; Darke, AK; Ford, LG; Ganz, PA; Gaziano, JM; Goodman, GE; Goodman, PJ; Hartline, JA; Jagpal, TJ; Karp, DD; Klein, EA; Kristal, AR; Lieber, MM; Lippman, SM; Lucia, MS; Meyskens, FL; Minasian, LM; Parnes, HL; Parsons, JK; Probstfield, JL; Santella, RM; Taylor, PR; Thompson, IM; Walther, P; Winquist, E | 1 |
| Du, Q; Huang, Z; Lin, L; Momin, RK; Sheng, J | 1 |
| Klein, EA | 2 |
| Do, KA; Efstathiou, E; Kim, J; Lippman, SM; Logothetis, CJ; McDonnell, TJ; Menter, DG; Pettaway, CA; Pisters, LL; Stephens, C; Taylor, R; Thall, PF; Troncoso, P; Tsavachidou, D; Vakar-Lopez, F; Wang, X; Wen, S; Wood, CG | 1 |
| El-Bayoumy, K | 1 |
| Bonorden, MJ; Cleary, MP; Hu, H; Lee, HJ; Li, GX; Liao, JD; Lü, J; Wang, L; Zhang, Y | 1 |
| Fairweather-Tait, S; Hurst, R | 1 |
| Combs, GF; Rayman, MP; Waters, DJ | 1 |
| Buntinx, F; Goossens, ME; Zeegers, MP | 1 |
| Bosland, MC; Johnson, WD; Lubet, RA; McCormick, DL; Rao, KV; Steele, VE | 1 |
| Bosland, MC; Horton, L; Lasano, S; Ozten, N | 1 |
| El-Bayoumy, K; Facompre, ND; Pinto, JT; Sinha, R; Sun, YW | 1 |
| Anderson, LB; Lü, J; Wang, L; Witthuhn, B; Xu, Y; Zhang, J | 1 |
| Dunn, BK; Ford, LG; Minasian, LM; Richmond, ES; Ryan, AM | 1 |
| Anderson, LB; Li, G; Lü, J; Wang, L; Witthuhn, B; Xu, Y; Zhang, J | 1 |
| de Rosa, V; Diamond, AM; Douki, T; Erkekoğlu, P; Favier, A; Forestier, A; Hincal, F; Rachidi, W | 1 |
| Bostwick, DG; Chiang, EC; Combs, GF; Kengeri, SS; Morris, JS; Shen, S; Waters, DJ | 1 |
| Chen, M; Huang, J; Li, R; Ni, J; Yeh, S; Zhang, Y | 1 |
| Bhamre, S; Cohen, HJ; Whitin, JC | 1 |
| Dalkin, BL; Jay Gandolfi, A; Kopplin, MJ; Nagle, RB; Nyman, DW; Suzanne Stratton, M | 1 |
| Cho, SD; Dong, Y; Ip, C; Jiang, C; Kang, KS; Lee, YS; Lü, J; Malewicz, B; Young, CY | 1 |
| Brodzeller, T; Datta, MW; Dhir, R; Hessner, MJ; Liu, H; Matysiak, B; Pollard, M; Schlicht, M; Suckow, M; Tonellato, P; Wen, X; Zhou, G | 1 |
| Babaian, RJ; Ho, SM; Kim, J; Lam, YW; Lieberman, R; Lippman, SM; Logothetis, C; McDonnell, TJ; Pettaway, CA; Pisters, LL; Sabichi, AL; Sun, P; Troncoso, P; Wood, CG | 1 |
| Basler, JW; Caton, JR; Crawford, ED; Lee, JJ; Lerner, SP; Lippman, SM; Marshall, JR; Menter, DG; Miles, BJ; Minasian, LM; Pisters, LL; Sabichi, AL; Tangen, CM; Taylor, RJ; Thompson, IM | 1 |
| Bosello, V; Bulato, C; Maiorino, M; Ursini, F | 1 |
| Domann, FE; Zhao, R; Zhong, W | 1 |
| Barranco, WT; Eckhert, CD; Hudak, PF | 1 |
| Brooks, JD; Zhao, H | 1 |
| Combs, GF; Hu, H; Lee, HJ; Li, GX; Liao, JD; Lü, J; Wang, Z; Watts, JC | 1 |
| Baines, AT; Basye, JL; Calley, C; Clark, LC; Nelson, MA; Payne, CM; Redman, C; Roe, D; Scott, JA | 1 |
| Clark, LC; Marshall, JR | 1 |
| Ferro, MA; Heinemann, D; Smith, PJ; Symes, MO | 1 |
2 review(s) available for selenomethionine and Cancer of Prostate
| Article | Year |
|---|---|
Mechanisms of selenium chemoprevention and therapy in prostate cancer.
Topics: Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Humans; Male; Prostatic Neoplasms; Selenium; Selenocysteine; Selenomethionine | 2008 |
A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Topics: Aged; Animals; Humans; Male; Middle Aged; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selenomethionine; Vitamin E | 2010 |
10 trial(s) available for selenomethionine and Cancer of Prostate
| Article | Year |
|---|---|
Effect of Dietary Methylseleninic Acid and Se-Methylselenocysteine on Carcinogen-Induced, Androgen-Promoted Prostate Carcinogenesis in Rats.
Topics: Androgens; Animals; Antioxidants; Carcinogenesis; Carcinogens; Diet; Disease Models, Animal; Humans; Male; Mice; Organoselenium Compounds; Prostate; Prostatic Neoplasms; Rats; Selenium; Selenocysteine; Selenomethionine | 2022 |
Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial.
Topics: Aged; Aging; Antioxidants; Cataract; Cataract Extraction; Double-Blind Method; Drug Combinations; Endpoint Determination; Humans; Incidence; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Risk Factors; Selenomethionine; Surveys and Questionnaires; Vitamin E | 2015 |
Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention.
Topics: Adenoma; Aged; alpha-Tocopherol; Antioxidants; Colorectal Neoplasms; Dietary Supplements; Humans; Incidence; Male; Middle Aged; Prostatic Neoplasms; Risk Factors; Selenomethionine; Sigmoidoscopy | 2017 |
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Topics: Aged; alpha-Tocopherol; Antioxidants; Dietary Supplements; Double-Blind Method; Humans; Male; Middle Aged; Neoplasms; Prostatic Neoplasms; Selenium; Selenomethionine; Treatment Outcome; Vitamin E | 2009 |
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer.
Topics: Aged; alpha-Tocopherol; Analysis of Variance; Anticarcinogenic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Confounding Factors, Epidemiologic; Drug Therapy, Combination; Feasibility Studies; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Immunohistochemistry; Ki-67 Antigen; Linear Models; Male; Microdissection; Middle Aged; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Prostate; Prostatectomy; Prostatic Neoplasms; Reproducibility of Results; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Selenomethionine; Treatment Failure; Tumor Suppressor Protein p53 | 2009 |
The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis.
Topics: Aged; Humans; Male; Middle Aged; Prostatic Neoplasms; Selenomethionine; Vitamin E | 2009 |
Prostatic response to supranutritional selenium supplementation: comparison of the target tissue potency of selenomethionine vs. selenium-yeast on markers of prostatic homeostasis.
Topics: Aging; Animals; Apoptosis; Cell Proliferation; Dietary Supplements; Dihydrotestosterone; DNA Damage; Dogs; Homeostasis; Male; Models, Animal; Prostate; Prostatic Neoplasms; Selenium; Selenomethionine; Testosterone; Yeasts | 2012 |
Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer.
Topics: Analysis of Variance; Antioxidants; Double-Blind Method; Humans; Male; Middle Aged; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Proteomics; Selenomethionine; Vitamin E | 2005 |
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Prostate; Prostatectomy; Prostatic Neoplasms; Selenium; Selenomethionine; Seminal Vesicles; Sensitivity and Specificity; Spectrometry, Fluorescence; Time Factors; Tissue Distribution | 2006 |
Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia.
Topics: Anticarcinogenic Agents; Arizona; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dietary Supplements; Double-Blind Method; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selenomethionine; Skin Neoplasms | 2001 |
28 other study(ies) available for selenomethionine and Cancer of Prostate
| Article | Year |
|---|---|
Phase III prostate cancer chemoprevention trials.
Topics: 5-alpha Reductase Inhibitors; Antioxidants; Chemoprevention; Clinical Trials, Phase III as Topic; Humans; Male; Prostatic Neoplasms; Risk Factors; Selenomethionine; Treatment Outcome; Vitamin E | 2014 |
Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
Topics: Adenocarcinoma; alpha-Tocopherol; Anticarcinogenic Agents; beta Carotene; Biomarkers, Tumor; Carotenoids; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Genistein; Humans; Lycopene; Male; Prostate-Specific Antigen; Prostatic Neoplasms; RNA, Messenger; Selenomethionine; Vitamins | 2008 |
Effects of selenomethionine on the gene expression profile of cloned human prostate cancer cells representing a phenotypic continuum of cancer progression.
Topics: Cell Line, Tumor; Disease Progression; Gene Expression Profiling; Humans; Male; Phenotype; Prostatic Neoplasms; Selenomethionine | 2008 |
Facile synthesis and anti-tumor cell activity of Se-containing nucleosides.
Topics: Cell Line, Tumor; Cells, Cultured; Deoxyuridine; Drug Screening Assays, Antitumor; Humans; Male; Prostatic Neoplasms; Selenomethionine; Thymidine | 2009 |
Selenium and vitamin E: interesting biology and dashed hope.
Topics: alpha-Tocopherol; Anticarcinogenic Agents; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selenomethionine; Treatment Failure | 2009 |
Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Cysteine; Enzyme-Linked Immunosorbent Assay; In Situ Nick-End Labeling; Insulin-Like Growth Factor I; Male; Mice; Mice, Transgenic; Organoselenium Compounds; Prostatic Neoplasms; Selenocysteine; Selenomethionine | 2009 |
Selenium and vitamin E supplementation for cancer prevention.
Topics: Antioxidants; Dietary Supplements; Humans; Male; Prostatic Neoplasms; Selenium; Selenomethionine; Vitamin E | 2009 |
Selenium and vitamin E supplementation for cancer prevention.
Topics: Antioxidants; Dietary Supplements; Humans; Male; Prostatic Neoplasms; Selenium; Selenomethionine; Vitamin E | 2009 |
Re: Selenium and vitamin E: interesting biology and dashed hope.
Topics: Animals; Anticarcinogenic Agents; Humans; Male; Meta-Analysis as Topic; Prostatic Neoplasms; Selenium; Selenocysteine; Selenomethionine; Vitamin E | 2009 |
Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate.
Topics: Adenocarcinoma; Alkylating Agents; alpha-Tocopherol; Androgens; Animals; Antioxidants; Cyproterone Acetate; Disease Models, Animal; Drug Therapy, Combination; Male; Methylnitrosourea; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Rats; Rats, Wistar; Selenium Compounds; Selenomethionine; Testosterone; Vitamin E | 2010 |
Selenomethionine and alpha-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model.
Topics: Adenocarcinoma; alpha-Tocopherol; Androgens; Animals; Antioxidants; Dietary Supplements; Disease Models, Animal; Drug Therapy, Combination; Estradiol; Estrogens; Male; Oxidative Stress; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Selenomethionine; Testosterone | 2010 |
1,4-phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells.
Topics: Androgen Antagonists; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Models, Biological; Oncogene Protein v-akt; Organoselenium Compounds; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Receptors, Androgen; Selenomethionine; Signal Transduction; Tumor Cells, Cultured | 2010 |
Proteomic profiling of potential molecular targets of methyl-selenium compounds in the transgenic adenocarcinoma of mouse prostate model.
Topics: Adenocarcinoma; Animals; Biomarkers, Pharmacological; Biomarkers, Tumor; Cysteine; Disease Models, Animal; Male; Metabolome; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Biological; Organoselenium Compounds; Prostatic Neoplasms; Proteomics; Selenium Compounds; Selenocysteine; Selenomethionine | 2010 |
Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds.
Topics: Animals; Anticarcinogenic Agents; Cysteine; Gene Expression Profiling; Gene Expression Regulation; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Organoselenium Compounds; Prostate; Prostatic Neoplasms; Protein Biosynthesis; Proteomics; RNA, Messenger; Selenium Compounds; Selenocysteine; Selenomethionine; Sodium Selenite; Xenograft Model Antitumor Assays | 2011 |
Low doses of selenium specifically stimulate the repair of oxidative DNA damage in LNCaP prostate cancer cells.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Anticarcinogenic Agents; Antioxidants; Cell Line, Tumor; Cell Survival; Deoxyguanosine; DNA Fragmentation; DNA Repair; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Humans; Hydrogen Peroxide; Male; Oxidation-Reduction; Oxidative Stress; Prostatic Neoplasms; Selenomethionine; Sodium Selenite; Thioredoxin-Disulfide Reductase; Ultraviolet Rays | 2012 |
Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery.
Topics: Anticarcinogenic Agents; Cell Cycle; Cell Cycle Proteins; Cell Division; DNA-Binding Proteins; E2F Transcription Factors; G1 Phase; Humans; Male; Prostatic Neoplasms; Retinoblastoma Protein; RNA, Messenger; Selenomethionine; Tocopherols; Transcription Factors; Tumor Cells, Cultured; Vitamin E | 2003 |
Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth.
Topics: Agar; Cell Division; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Selenium; Selenomethionine; Stem Cells; Tumor Cells, Cultured | 2003 |
Selenium and selenomethionine levels in prostate cancer patients.
Topics: Aged; Biomarkers, Tumor; Biopsy, Needle; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Humans; Male; Middle Aged; Prognosis; Prostatectomy; Prostatic Neoplasms; Reference Values; Sampling Studies; Selenium; Selenomethionine; Sensitivity and Specificity | 2004 |
Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription.
Topics: Androgens; Cell Death; Cell Line, Tumor; Humans; Male; Organoselenium Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Processing, Post-Translational; Receptors, Androgen; RNA, Messenger; Selenomethionine; Sodium Selenite; Time Factors; Transcription, Genetic | 2004 |
Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Cell Line, Tumor; DNA, Neoplasm; Expressed Sequence Tags; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Male; Neoplasm Proteins; Prostatic Neoplasms; Rats; Retinoid X Receptor alpha; RNA, Messenger; RNA, Neoplasm; Selenium; Selenomethionine; Species Specificity; Subtraction Technique | 2004 |
Effect of mercury on selenium utilization and selenoperoxidase activity in LNCaP cells.
Topics: Humans; Hydrogen Peroxide; Male; Mercury; Prostatic Neoplasms; Selenium; Selenocysteine; Selenomethionine; Selenoproteins; Sodium Selenite; Tumor Cells, Cultured | 2007 |
Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carbon-Sulfur Lyases; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Male; Mitochondria; Prostatic Neoplasms; Selenomethionine; Superoxides; Tumor Suppressor Protein p53 | 2006 |
Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States).
Topics: Anticarcinogenic Agents; Boric Acids; Boron; Cell Proliferation; Environment; Genistein; Humans; Male; Prostatic Neoplasms; Radiation, Ionizing; Regression Analysis; Risk Factors; Selenomethionine; Texas; Tumor Cells, Cultured; United States; Water | 2007 |
SELECTing the best.
Topics: Clinical Trials as Topic; Humans; Male; Prostatic Neoplasms; Selenomethionine | 2007 |
Selenomethionine induced transcriptional programs in human prostate cancer cells.
Topics: Humans; Male; Organoselenium Compounds; Prostatic Neoplasms; Selenomethionine; Transcription, Genetic; Tumor Cells, Cultured | 2007 |
Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Comet Assay; DNA Damage; Humans; Lymphocytes; Male; Mice; Mice, Nude; Neoplasm Transplantation; Organoselenium Compounds; Prostatic Neoplasms; Selenomethionine; Transplantation, Heterologous | 2008 |
Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Prostatic Neoplasms; Selenomethionine; Tumor Cells, Cultured | 1998 |
Effect of stilboestrol and testosterone on the incorporation of 75selenomethionine by prostatic carcinoma cells.
Topics: Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estradiol; Humans; Male; Neoplasm Proteins; Prostatic Neoplasms; Selenomethionine; Testosterone; Tumor Cells, Cultured | 1988 |